FDA OKs second treatment for neuromyelitis optica spectrum disorder
(HealthDay)—Uplizna (inebilizumab-cdon) injection is now approved to treat neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody positive, the U.S. Food and Drug Administration ...
Jun 15, 2020
0
2